Discover scientific publications on pharmacovigilance
Original research and thinking in the science of pharmacovigilance
This is a non-exhaustive list of scientific papers with key authors from the UMC. Most of the references link to full articles.
217 documents found.
-
Scientific publicationsSignal Selection and Follow-Up in Pharmacovigilance
The detection of unknown and unexpected connections between drug exposure and adverse events is one of the major challenges of pharmacovigilance. Drug Saf. 2002;25(6):459-65.
Author: Ronald H.B. Meyboom, Marie Lindquist, Antoine C.G. Egberts, I. Ralph Edwards
Date: 2002-05-01 -
Scientific publications
Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study
BMJ 2001;322:1207 Details of methods - Explanation of data mining methods (A Bate, R Orre, M Lindquist, I R Edwards) at https://www.bmj.com/content/suppl/2001/05/17/322.7296.1207.DC1
Author: David M Coulter, Andrew Bate, Ronald H B Meyboom, Marie Lindquist, I Ralph Edwards
Date: 2001-05-19 -
Scientific publicationsA Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database
The detection of new drug safety signals is of growing importance with ever more new drugs becoming available and exposure to medicines increasing. Drug Safety 2000 Dec; 23 (6): 533-542
Author: Marie Lindquist, Malin Ståhl, Andrew Bate, I. Ralph Edwards, Ronald H.B. Meyboom
Date: 2000-12-01 -
Scientific publicationsAn ABC of Drug-Related Problems
Practically all medicine-related problems can be classified in one basic system, taking into account their characteristics and distinctions. This system distinguishes between appropriate and inappropriate drug use, dose-related and dose unrelated problems, and types A (‘drug actions’), B (‘patient reactions’) and C (‘statistical’) adverse effects.Drug Saf. 2000;22(6):415-23.
Author: Ronald H.B. Meyboom, Marie Lindquist, Antoine C.G. Egberts
Date: 2000-08-01 -
Scientific publicationsPharmacovigilance in Perspective
Pharmacovigilance is more than spontaneous reporting alone, and the evaluation of marketed medicines is more than just pharmacovigilance. Drug Saf. 1999;21(6):429-47.
Author: Ronald H. B. Meyboom, Antoine C. G. Egberts, Frank W. J. Gribnau, Yechiel A. Hekster
Date: 1999-12-01 -
Scientific publications
A Bayesian neural network method for adverse drug reaction signal generation
European Journal of Clinical PharmacologyJuly 1998, Volume 54, Issue 4, pp 315–321
Author: A. Bate, M. Lindquist, I. R. Edwards, S. Olsson, R. Orre, A. Lansner, R. M. De Freitas
Date: 1998-07-01 -
Scientific publicationsThe Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts
The rationale for setting up the WHO International Programme for Adverse Reaction Monitoring, 30 years ago was to make it possible to identify rare adverse drug reactions (ADRs) that could not be found through clinical trial programmes.Drug Saf. 1998;19(1):1-10.
Author: Sten Olsson
Date: 1998-07-01 -
Scientific publicationsCausal or Casual? The Role of Causality Assessment in Pharmacovigilance
As with any other study method, ‘spontaneous reporting’ in pharmacovigilance is a process of data acquisition, assessment, presentation and interpretation.Drug Saf. 1997;17(6):374-89.
Author: Ronald H. B. Meyboom, Yechiel A. Hekster, Antoine C. G. Egberts, Frank W. J. Gribnau, I. Ralph Edwards
Date: 1997-12-01 -
Scientific publicationsThe Challenge of Effectively Communicating Risk-Benefit Information
Although the techniques involved in drug safety monitoring (pharmacovigilance) have dramatically improved in recent years, communication of these issues to health professionals and the public lags far behind.Drug Saf. 1997;17(4):216-27.
Author: I. Ralph Edwards, Bruce Hugman
Date: 1997-10-01 -
Scientific publicationsPrinciples of Signal Detection in Pharmacovigilance
Adverse drug effects are manifold and heterogenous.Drug Saf. 1997;16(6):355-65.
Author: Ronald H. B. Meyboom, Antoine C. G. Egberts, I. Ralph Edwards, Yechiel A. Hekster, Fred H. P. de Koning, Frank W. J. Gribnau
Date: 1997-06-01 -
Scientific publications
Who cares about pharmacovigilance?
European Journal of Clinical Pharmacology. October 1997, Volume 53, Issue 2, pp 83–88.
Author: I. R. Edwards
Date: 1997-05-27 -
Scientific publicationsConcepts in Risk-Benefit Assessment - A Simple Merit Analysis of a Medicine?
The term ‘benefit-risk ratio’ is often used as a general term linked to the use of a medicine.Drug Saf. 1996;15(1):1-7.
Author: I. Ralph Edwards, Bengt-Erik Wiholm, Carlos Martinez
Date: 1996-07-01 -
Scientific publicationsHarmonisation in Pharmacovigilance
Throughout the world there is considerable activity in the area of drug safety, pharmacovigilance and pharmacoepidemiology.Drug Saf. 1994;10(2):93-102.
Author: I. Ralph Edwards, Cecilia Biriell
Date: 1992-02-01 -
Scientific publications
Skin reactions and fever with indapamide.
BMJ. 1987;295:1313.
Author: Stricker BHC, Biriell C.
Date: 1987-11-21 -
Scientific publications
Skin reactions to terfenadine.
Br Med J (Clin Res Ed) 1986;293:536.
Author: Stricker BH, va Dijke CPH, Isaacs AJ, Lindquist M.
Date: 1986-08-30 -
Scientific publications
Acute hypersensitivity reactions to paracetamol.
BMJ. 1985;291:938-9.
Author: Stricker BHC, Meyboom RHB, Lindquist M.
Date: 1985-10-05 -
Scientific publications
Photosensitivity during treatment with azapropazone.
Br Med J (Clin Res Ed) 1985;291:939.
Author: Olsson S, Biriell C, Boman G.
Date: 1985-10-05